Artelo Biosciences
ARTL
4 hedge funds and large institutions have $34.4K invested in Artelo Biosciences in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0.06% less ownership
Funds ownership: 0.1% → 0.04% (-0.06%)
50% less funds holding
Funds holding: 8 → 4 (-4)
55% less capital invested
Capital invested by funds: $76.4K → $34.4K (-$42K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.64K |
| 2 |
Morgan Stanley
New York
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$44K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$164 |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$104 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$29 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $27.5K | – | – | – |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $6.72K | +$3.64K | +148 | +124% |
|
|
3
Morgan Stanley
New York
| $56 | +$25 | +1 | +100% |
|
4
Wells Fargo
San Francisco,
California
| $31 | – | – | – |
|
|
RIL
5
Rothschild Investment LLC
Chicago,
Illinois
| $11 | – | – | – |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $9 | – | – | – |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $1 | – | – | – |
|
|
HF
8
HRT Financial
New York
| – | -$44K | -1,682 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$164 | -6 | Closed |
|
|
10
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$104 | -4 | Closed |
|
|
11
Fidelity Investments
Boston,
Massachusetts
| – | -$29 | -1 | Closed |
|
ARTL Hedge Fund Activity: Q4 2023 in Review
4 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2023, worth a combined $34.4K — down 55% from $76.4K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ARTL and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $3.64K. The largest seller was HRT Financial, exiting entirely with an estimated $44K sold.
- 4 institutional investors held Artelo Biosciences (ARTL) as of Q4 2023, down from 8 in Q3 2023.
- Funds reported $34.4K of Artelo Biosciences stock for Q4 2023, down 55% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences positions in Q4 2023 and 4 closed out, a net change of -4 holders.
- The largest Artelo Biosciences buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $3.64K added.
- The largest Artelo Biosciences seller in Q4 2023 was HRT Financial, an estimated $44K sold.
Based on aggregated 13F filings for Q4 2023.